Your browser doesn't support javascript.
loading
Potential of postbiotics for the treatment of metabolic disorders.
Mishra, Neeraj; Garg, Ashish; Ashique, Sumel; Bhatt, Shvetank.
Afiliação
  • Mishra N; Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior 474005, India.
  • Garg A; Department of Pharmaceutics, Guru RamdasKhalsa Institute of Science and Technology (Pharmacy), Jabalpur 483001, Madhya Pradesh, India.
  • Ashique S; Department of Pharmaceutical Sciences, Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India.
  • Bhatt S; Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune 411038, Maharashtra, India. Electronic address: shvetankbhatt@gmail.com.
Drug Discov Today ; 29(4): 103921, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38382867
ABSTRACT
Postbiotics, the next generation of probiotics, are extracts that are free of living and nonviable bacteria and show strong modulatory effects on the gut flora. Examples include vitamin B12, vitamin K, folate, lipopolysaccharides, enzymes, and short-chain fatty acids (SCFAs), representing a subset of essential nutrients commonly found in the human diet. Postbiotics have been observed to demonstrate antiobesity and antidiabetic effects through a variety of mechanisms. These pathways primarily involve an elevation in energy expenditure, a decrease in the formation and differentiation of adipocytes and food intake, modification of lipid and carbohydrate absorption and metabolism, and regulation of gut dysbiosis. Based on these above effects and mechanisms, the use of postbiotics can be considered as potential strategy for the treatment of metabolic disorders.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Probióticos / Doenças Metabólicas Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Probióticos / Doenças Metabólicas Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article